March 2026                                                                                     

BioStem & BioTissue Integration – Customer FAQs

1. What is changing?

BioStem Technologies has acquired BioTissue’s Surgical & Wound Care business, including the Neox® & Clarix® product franchises. This expands BioStem’s offerings into Acute Wound Care & Soft‑Tissue Repair, while maintaining all existing Chronic Wound Care products.

2. Will the products I use stay the same?

Yes. All BioTissue Surgical & Wound Care products remain available, and all BioStem products remain unchanged. This integration expands the portfolio; it does not remove or replace any products.

3. Will my ordering process change?

No. Your current ordering process, contacts, and support channels remain the same. Any future updates will be communicated well in advance.

4. Will my pricing or GPO contracts change?

No. All existing pricing and GPO agreements remain in place. The acquisition expands BioStem’s GPO footprint, which will improve access for many facilities.

5. Will my Sales Representative change?

No. Your current Representative, whether from BioStem or BioTissue, will continue to support you. The combined commercial team is being integrated under unified leadership, but customer relationships will remain the same.

6. Are there changes to product manufacturing or regulatory status?

No.

  • BioStem products continue to be manufactured using the BioRetain® method at the FDA‑registered, AATB‑accredited Pompano Beach facility.
  • BioTissue’s CryoTek® cryopreserved products will continue to be manufactured using their established processes.
  • There will be no changes to indications, regulatory classifications, or clinical use.

7. How does this benefit my patients?

Clinicians gain access to a broader suite of patient solutions across Acute & Chronic Wound Care. The combined portfolio supports a wider range of clinical scenarios, while maintaining the safety, consistency, and performance you have come to expect.

8. Will my clinical support or education resources change?

Clinical support will expand as the combined team brings together experienced specialists from both organizations. Education, training, and in‑service resources will continue uninterrupted.

9. Will there be any changes to product availability or supply?

No. Supply remains uninterrupted. The combined commercial & operational infrastructure strengthens long‑term stability & product availability.

10. Who should I contact with questions?

  • Your current BioStem or BioTissue Representative will remain your primary points of contact.
  • You may also reach out to BioStem’s Customer Support Team for product, ordering, or clinical inquiries at 800-xxx-xxxx.